Neonatal abstinence syndrome after methadone or buprenorphine exposure

New England Journal of Medicine

Volumn 363, Issue 24, 2010, Pages 2320-2331

  Jones, Hendrée E ^a   Kaltenbach, Karol ^b   Heil, Sarah H ^c   Stine, Susan M ^d   Coyle, Mara G ^e   Arria, Amelia M ^f   O'Grady, Kevin E ^g   Selby, Peter ^h   Martin, Peter R ⁱ   Fischer, Gabriele ^j  

^a JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b THOMAS JEFFERSON UNIVERSITY   (United States)

^c UNIVERSITY OF VERMONT   (United States)

^d WAYNE STATE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^e BROWN UNIVERSITY   (United States)

^f UNIVERSITY OF MARYLAND   (United States)

^g UNIVERSITY OF MARYLAND   (United States)

^h UNIVERSITY OF TORONTO   (Canada)

ⁱ VANDERBILT UNIVERSITY SCHOOL OF MEDICINE   (United States)

^j MEDICAL UNIVERSITY OF VIENNA   (Austria)

more..

Author keywords

[No Author keywords available]

Indexed keywords

BUPRENORPHINE; METHADONE; MORPHINE; PLACEBO;

ADULT; ARTICLE; CARDIOVASCULAR DISEASE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG WITHDRAWAL; FEMALE; FOLLOW UP; HEAD CIRCUMFERENCE; HOSPITALIZATION; HUMAN; LENGTH OF STAY; MAJOR CLINICAL STUDY; NEWBORN; OPIATE ADDICTION; PREGNANT WOMAN; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; TREATMENT DURATION; TREATMENT OUTCOME; UNSPECIFIED SIDE EFFECT; WITHDRAWAL SYNDROME;

EID: 78649805581     PISSN: 00284793     EISSN: 15334406     Source Type: Journal    
DOI: 10.1056/NEJMoa1005359     Document Type: Article

References (44)

1. Hulse GK, Milne E, English DR, Holman CD. The relationship between maternal use of heroin and methadone and infant birth weight. Addiction 1997;92:1571-9.
2. Kandall SR, Albin S, Gartner LM, Lee KS, Edelman A, Lowinson J. The narcotic-dependent mother: fetal and neonatal consequences. Early Hum Dev 1977;1:159-69.
3. Messinger DS, Bauer CR, Das A, et al. The Maternal Lifestyle Study: cognitive, motor, and behavioral outcomes of cocaine-exposed and opiate-exposed infants through three years of age. Pediatrics 2004;113:1677-85.
4. Winklbaur B, Kopf N, Ebner N, Jung E, Thau K, Fischer G. Treating pregnant women dependent on opioids is not the same as treating pregnancy and opioid dependence: a knowledge synthesis for better treatment for women and neonates. Addiction 2008;103:1429-40.
5. Lester BM, Andreozzi L, Appiah L. Substance use during pregnancy: time for policy to catch up with research. Harm Reduct J 2004;1:5-49.
6. Lifschitz MH, Wilson GS, Smith EO, Desmond MM. Factors affecting head growth and intellectual function in children of drug addicts. Pediatrics 1985;75:269-74.
7. Kandall SR. Improving treatment for drug-exposed infants. Rockville, MD: Department of Health and Human Services, 1993.
8. Mattick RP, Breen C, Kimber J, Davoli M. Methadone maintenance therapy versus no opioid replacement therapy for opioid dependence. Cochrane Database Syst Rev 2009;3:CD002209.
9. Jones HE, O'Grady KE, Malfi D, Tuten M. Methadone maintenance vs. methadone taper during pregnancy: maternal and neonatal outcomes. Am J Addict 2008;17:372-86.
10. Kaltenbach K, Berghella V, Finnegan L. Opioid dependence during pregnancy: effects and management. Obstet Gynecol Clin North Am 1998;25:139-51.
11. Finnegan LP, Kaltenbach K. Neonatal abstinence syndrome. In Hoekelman RA, Friedman SB, Nelson NM, et al., eds. Primary pediatric care. 2nd ed. St. Louis: Mosby, 1992:1367-78.
12. Mattick RP, Kimber J, Breen C, Davoli M. Buprenorphine maintenance versus placebo or methadone maintenance for opioid dependence. Cochrane Database Syst Rev 2008;2:CD002207.
13. Walsh SL, Preston KL, Bigelow GE, Stitzer ML. Acute administration of buprenorphine in humans: partial agonist and blockade effects. J Pharmacol Exp Ther 1995;274:361-72.
14. Jasinski DR, Pevnick JS, Griffith JD. Human pharmacology and abuse potential of the analgesic buprenorphine: a potential agent for treating narcotic addiction. Arch Gen Psychiatry 1978;35:501-16.
15. Mello NK, Mendelson JH. Buprenorphine suppresses heroin use by heroin addicts. Science 1980;207:657-9.
16. Fischer G, Johnson RE, Eder H, et al. Treatment of opioid-dependent pregnant women with buprenorphine. Addiction 2000;95:239-44.
17. Johnson RE, Jones HE, Jasinski DR, et al. Buprenorphine treatment of pregnant opioid-dependent women: maternal and neonatal outcomes. Drug Alcohol Depend 2001;63:97-103.
18. Ebner N, Rohrmeister K, Winklbaur B, et al. Management of neonatal abstinence syndrome in neonates born to opioid maintained women. Drug Alcohol Depend 2007;87:131-8.
19. Schindler SD, Eder H, Ortner R, Rohrmeister K, Langer M, Fischer G. Neonatal outcome following buprenorphine maintenance during conception and throughout pregnancy. Addiction 2003;98:103-10.
20. Hytinantti T, Kahila H, Renlund M, et al. Neonatal outcome of 58 infants exposed to maternal buprenorphine in utero. Acta Paediatr 2008;97:1040-4.
21. Johnson RE, Jones HE, Fischer G. Use of buprenorphine in pregnancy: patient management and effects on the neonate. Drug Alcohol Depend 2003;70:S87-S101.
22. Lejeune C, Simmat-Durand L, Gourarier L, Aubisson S. Prospective multicenter observational study of 260 infants born to 259 opiate-dependent mothers on methadone or high-dose buprenophine substitution. Drug Alcohol Depend 2006; 82:250-7.
23. Bakstad B, Sarfi M, Welle-Strand GK, Ravndal E. Opioid maintenance treatment during pregnancy: occurrence and severity of neonatal abstinence syndrome: a national prospective study. Eur Addict Res 2009;15:128-34.
24. Kakko J, Heilig M, Sarman I. Buprenorphine and methadone treatment of opiate dependence during pregnancy: comparison of fetal growth and neonatal outcomes in two consecutive case series. Drug Alcohol Depend 2008;96:69-78.
25. Fischer G, Ortner R, Rohrmeister K, et al. Methadone versus buprenorphine in pregnant addicts: a double-blind, double-dummy comparison study. Addiction 2006;101:275-81.
26. Jones HE, Johnson RE, Jasinski DR, et al. Buprenorphine versus methadone in the treatment of pregnant opioid-dependent patients: effects on the neonatal abstinence syndrome. Drug Alcohol Depend 2005;79:1-10.
27. Goldkind SF, Sahin L, Gallauresi B. Enrolling pregnant women in research - lessons from the H1N1 influenza pandemic. N Engl J Med 2010;362:2241-3.
28. Jones HE, Martin PR, Heil SH, et al. Treatment of opioid-dependent pregnant women: clinical and research issues. J Subst Abuse Treat 2008;35:245-59.
29. Jones HE, Johnson RE, Jasinski DR, Milio L. Randomized controlled study transitioning opioid-dependent pregnant women from short-acting morphine to buprenorphine or methadone. Drug Alcohol Depend 2005;78:33-8.
30. Unger AS, Martin PR, Kaltenbach K, et al. Clinical characteristics of Central European and North American samples of pregnant women screened for opioid agonist treatment. Eur Addict Res 2010;16:99-107.
31. Stine SM, Heil SH, Kaltenbach K, et al. Characteristics of opioid-using pregnant women who accept or refuse participation in a clinical trial: final screening results from the MOTHER study. Am J Drug Alcohol Abuse 2009;35:429-33.
32. Johnson RE, Chutuape MA, Strain EC, Walsh SL, Stitzer ML, Bigelow GE. A comparison of levomethadyl acetate, buprenorphine, and methadone for opioid dependence. N Engl J Med 2000;343:1290-7.
33. Ling W, Wesson DR, Charuvastra C, Klett J. A controlled trial comparing buprenorphine and methadone maintenance in opioid dependence. Arch Gen Psychiatry 1996;53:401-7.
34. Ling W, Wesson DR. Clinical efficacy of buprenorphine: comparisons to methadone and placebo. Drug Alcohol Depend 2003;70:Suppl:S49-S57.
35. D'Apolito K. A scoring system for assessing neonatal abstinence syndrome. Seattle: University of Washington, School of Nursing, 1994.
36. Jansson LM, Velez M, Harrow C. The opioid-exposed newborn: assessment and pharmacologic management. J Opioid Manag 2009;5:47-55.
37. Shrout PE, Fleiss JL. Intraclass correlations: uses in assessing rater reliability. Psychol Bull 1979;86:420-8.
38. Levran O, O'Hara K, Peles E, et al. ABCB1 (MDR1) genetic variants are associated with methadone doses required for effective treatment of heroin dependence. Hum Mol Genet 2008;17:2219-27.
39. Hemauer SJ, Patrikeeva SL, Nanovskaya TN, Hankins GD, Ahmed MS. Opiates inhibit paclitaxel uptake by P-glycoprotein in preparations of human placental inside-out vesicles. Biochem Pharmacol 2009;78:1272-8.
40. Bell J, Trinh L, Butler B, Randall D, Rubin G. Comparing retention in treatment and mortality in people after initial entry to methadone and buprenorphine treatment. Addiction 2009;104:1193-200.
41. Fischer G, Gombas W, Eder H, et al. Buprenorphine versus methadone maintenance for the treatment of opioid dependence. Addiction 1999;94:1337-47.
42. Rosado J, Walsh SL, Bigelow GE, Strain EC. Sublingual buprenorphine/naloxone precipitated withdrawal in subjects maintained on 100 mg of daily methadone. Drug Alcohol Depend 2007; 90:261-9.
43. Mattick RP, Ali R, White JM, O'Brien S, Wolk S, Danz C. Buprenorphine versus methadone maintenance therapy: a randomized double-blind trial with 405 opioiddependent patients. Addiction 2003;98:441-52.
44. Yuferov V, Levran O, Proudnikov D, Nielsen DA, Kreek MJ. Search for genetic markers and functional variants involved in the development of opiate and cocaine addiction and treatment. Ann N Y Acad Sci 2010;1187:184-207.